Sandostatin therapy in sarcoidosis
Phase 2
Completed
- Conditions
- Sarcoidosis10003816
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 20
Inclusion Criteria
* Age above 18 years with obtained written consent
* Have biopsy-proven symptomatic, stable, chronic sarcoidosis for minimal three years.
* Have a positive SRS
* Involvement of skin, joint, lymph nodes or lung. Patients with pulmonary involvement have a diffusing capacity between 60 and 75 percent.
Exclusion Criteria
* Corticosteroid use up to three months prior of trial
* Chronic renal failure defined as a GFR below 50%
* Liver disease
* Have an indication for intensifying immunosuppressive therapy; threatening organ damage
* Have failed on earlier anti TNF-* therapy
* Have an underlying cardiac disease
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>To evaluate efficacy of SST in a subset of patients that are<br /><br>refractory/intolerant for corticosteroid therapy by a change in uptake on SRS.<br /><br>Change in uptake in SRS, defined as improved, no change, worse.</p><br>
- Secondary Outcome Measures
Name Time Method <p>To study the composite clinical score using the following parameters.<br /><br>Measurements of ESR, CRP, full blood count, lysozyme, ACE, 25-hydroxyvitamin<br /><br>D, 1,25-dihydroxyvitamin D3 sIL-2R. Quality of life score assessment with<br /><br>RAND-36 will be conducted. When applicable lung-function test with FVC and DLCO<br /><br>and skin evaluation will take place. </p><br>